Logo image of ENDP

ENDO INTERNATIONAL PLC (ENDP) Stock Fundamental Analysis

NASDAQ:ENDP - Nasdaq - IE00BJ3V9050 - Common Stock - Currency: USD

0.2926  -0.02 (-5%)

After market: 0.26 -0.03 (-11.14%)

Fundamental Rating

1

ENDP gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 194 industry peers in the Pharmaceuticals industry. ENDP has a bad profitability rating. Also its financial health evaluation is rather negative. ENDP has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ENDP was profitable.
ENDP Yearly Net Income VS EBIT VS OCF VS FCFENDP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 0 -1B -2B -3B

1.2 Ratios

Industry RankSector Rank
ROA -40.81%
ROE N/A
ROIC 8.07%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ENDP Yearly ROA, ROE, ROICENDP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 200 -200 -400

1.3 Margins

Industry RankSector Rank
OM 19.02%
PM (TTM) -93.31%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ENDP Yearly Profit, Operating, Gross MarginsENDP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 50 -50

More info and screens

2

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), ENDP is creating some value.
Compared to 1 year ago, ENDP has more shares outstanding
Compared to 1 year ago, ENDP has a worse debt to assets ratio.
ENDP Yearly Shares OutstandingENDP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 50M 100M 150M 200M
ENDP Yearly Total Debt VS Total AssetsENDP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 5B 10B 15B

2.2 Solvency

ENDP has an Altman-Z score of -3.02. This is a bad value and indicates that ENDP is not financially healthy and even has some risk of bankruptcy.
A Debt/Equity ratio of -2.52 indicates that ENDP is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity -2.52
Debt/FCF N/A
Altman-Z -3.02
ROIC/WACC1.22
WACC6.62%
ENDP Yearly LT Debt VS Equity VS FCFENDP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 2B 4B 6B 8B

2.3 Liquidity

A Current Ratio of 1.86 indicates that ENDP should not have too much problems paying its short term obligations.
ENDP has a Quick Ratio of 1.62. This is a normal value and indicates that ENDP is financially healthy and should not expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 1.86
Quick Ratio 1.62
ENDP Yearly Current Assets VS Current LiabilitesENDP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 1B 2B 3B

More info and screens

0

3. Growth

3.1 Past

The earnings per share for ENDP have decreased strongly by -12.08% in the last year.
Measured over the past years, ENDP shows a decrease in Earnings Per Share. The EPS has been decreasing by -8.54% on average per year.
The Revenue has decreased by -1.56% in the past year.
ENDP shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -5.68% yearly.
EPS 1Y (TTM)-12.08%
EPS 3Y1.48%
EPS 5Y-8.54%
EPS Q2Q%-95.38%
Revenue 1Y (TTM)-1.56%
Revenue growth 3Y0.52%
Revenue growth 5Y-5.68%
Sales Q2Q%-20.27%

3.2 Future

The Earnings Per Share is expected to decrease by -34.53% on average over the next years. This is quite bad
Based on estimates for the next years, ENDP will show a decrease in Revenue. The Revenue will decrease by -8.13% on average per year.
EPS Next Y-57.56%
EPS Next 2Y-45.48%
EPS Next 3Y-38.91%
EPS Next 5Y-34.53%
Revenue Next Year-18.43%
Revenue Next 2Y-12.85%
Revenue Next 3Y-9.64%
Revenue Next 5Y-8.13%

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ENDP Yearly Revenue VS EstimatesENDP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 1B 2B 3B 4B
ENDP Yearly EPS VS EstimatesENDP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 1 2 3 4

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 0.13, which indicates a rather cheap valuation of ENDP.
Compared to an average S&P500 Price/Earnings ratio of 29.63, ENDP is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 0.33, the valuation of ENDP can be described as very cheap.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.68, ENDP is valued rather cheaply.
Industry RankSector Rank
PE 0.13
Fwd PE 0.33
ENDP Price Earnings VS Forward Price EarningsENDP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 7.29
ENDP Per share dataENDP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10

4.3 Compensation for Growth

ENDP's earnings are expected to decrease with -38.91% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-45.48%
EPS Next 3Y-38.91%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ENDP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENDO INTERNATIONAL PLC

NASDAQ:ENDP (8/25/2022, 10:28:44 PM)

After market: 0.26 -0.03 (-11.14%)

0.2926

-0.02 (-5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-09 2022-08-09/bmo
Earnings (Next)11-07 2022-11-07
Inst Owners0%
Inst Owner Change0%
Ins Owners2.12%
Ins Owner Change0%
Market Cap68.80M
Analysts42.86
Price Target1.02 (248.6%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 0.13
Fwd PE 0.33
P/S 0.02
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 7.29
EPS(TTM)2.33
EY796.31%
EPS(NY)0.9
Fwd EY306.77%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS11.83
BVpS-13.6
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -40.81%
ROE N/A
ROCE N/A
ROIC 8.07%
ROICexc N/A
ROICexgc 26.18%
OM 19.02%
PM (TTM) -93.31%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity -2.52
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.86
Quick Ratio 1.62
Altman-Z -3.02
F-Score5
WACC6.62%
ROIC/WACC1.22
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.08%
EPS 3Y1.48%
EPS 5Y-8.54%
EPS Q2Q%-95.38%
EPS Next Y-57.56%
EPS Next 2Y-45.48%
EPS Next 3Y-38.91%
EPS Next 5Y-34.53%
Revenue 1Y (TTM)-1.56%
Revenue growth 3Y0.52%
Revenue growth 5Y-5.68%
Sales Q2Q%-20.27%
Revenue Next Year-18.43%
Revenue Next 2Y-12.85%
Revenue Next 3Y-9.64%
Revenue Next 5Y-8.13%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A